Pharmstandard 2016 AR2
The report highlights Pharmstandard's performance in 2016, during which the company achieved a 30% increase in revenues to RR 62 billion, confirming its industry leadership in Russia. Pharmstandard transitioned to a private company following a mandatory squeeze-out by Augment Investments Limited. The company continued to expand its domestic production and localized manufacturing of pharmaceuticals in partnership with global leaders. Additionally, Pharmstandard invested over RR 2.9 billion in production upgrades and GMP compliance, while also focusing on human capital development and corporate social responsibility initiatives.
Company: Pharmstandard
Sector: Manufacturing
Country: Russia
Year: 2016
Type: AR2
Pages: 71
Back to company
Pharmstandard
Annual Report
The report highlights Pharmstandard's performance in 2016, during which the company achieved a 30% increase in revenues to RR 62 billion, confirming its industry leadership in Russia. Pharmstandard transitioned to a private company following a mandatory squeeze-out by Augment Investments Limited. The company continued to expand its domestic production and localized manufacturing of pharmaceuticals in partnership with global leaders. Additionally, Pharmstandard invested over RR 2.9 billion in production upgrades and GMP compliance, while also focusing on human capital development and corporate social responsibility initiatives.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2016
Reporting Period
Jan 1, 2016 - Dec 31, 2016
Fiscal Year
2016
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women in Management
Employees